ADMET Predictor® 11 is Here: AI & ML for Drug Discovery and Development

Keywords: admet predictor, AI-Driven Drug Design, CYP inhibition, machine learning (ML), pKa model
Software: ADMET Predictor®
Division: PBPK

Your competitors are using AI and machine learning for ADMET prediction—are you?

Learn how you can get started or get ahead with the upcoming release of ADMET Predictor 11. In this webinar, you’ll get a sneak peek of the latest version of the flagship machine learning platform for ADMET modeling and its extended capabilities for data analysis, metabolism prediction, and AI-driven drug design. Eric Jamois, Director of Business Development will be hosting, and the VP of ADMET Cheminformatics, David Miller, will be walking through the new features of AP11.

They’ll cover components including:
– Greatly improved pKa model incorporating large contribution of experimental data from pharmaceutical partners
– New and updated models of CYP inhibition
– New functionality for performing 3D similarity screens based on shape and pharmacophore features
– Significant enhancements to the AI-driven drug design module

Speaker: David Miller

Moderator: Eric Jamois